University of Parma

Accuro Epidural Guidance Device Demonstrated Superior for Spinal Anesthesia Administration Compared to Palpation & Conventional Ultrasound in a Parturient With Extreme Obesity

Retrieved on: 
Tuesday, August 16, 2022
FDA, Subcutaneous tissue, Epidural space, Patient satisfaction, Obesity, CEO, GLOBE, Technology, Pregnancy, Patient, Â, Accuro Healthcare Solutions, Anesthesiology, Acquisition, History of neuraxial anesthesia, Skin, What's Your Flava?, Safety, Critical care, Palpation, ISO, University, Dura mater, Dura, University of Parma, BMI, Medical imaging

As reported in the study, a patient requesting epidural analgesia for labor presented with a calculated BMI of 64.5 kg.

Key Points: 
  • As reported in the study, a patient requesting epidural analgesia for labor presented with a calculated BMI of 64.5 kg.
  • Secondarily, acquiring standard ultrasound imaging of the lumbar spine was ineffective in identifying target structures due to the amount of subcutaneous tissue.
  • It may offer a new advantage in improving outcomes and training for operators not experienced in neuraxial ultrasound techniques.
  • RIVANNA's technology platform combines the benefits of ultrasound with bone imaging capabilities of x-ray to fill unmet clinical needs.

CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer

Retrieved on: 
Thursday, April 7, 2022
Company, Therapy, NASDAQ, Shire (pharmaceutical company), Leadership, Multimedia, Board, University of Parma, CMO, CAR, Biotechnology, School, CSO, Cancer, CEO, View, Pfizer, Biology, LADAR, Acquisition, Development, Research and development, University, Patient, Medical device, Pharmaceutical industry, Sanofi

Prior to joining CARsgen, Dr. Baffa served as Chief Medical Officer and Executive Vice President of Research & Development at Ziopharm Oncology (NASDAQ: ZIOP), which was rebranded to Alaunos in January 2022.

Key Points: 
  • Prior to joining CARsgen, Dr. Baffa served as Chief Medical Officer and Executive Vice President of Research & Development at Ziopharm Oncology (NASDAQ: ZIOP), which was rebranded to Alaunos in January 2022.
  • Prior to Ziopharm Oncology, Dr. Baffa was Head of Research & Development and Chief Medical Officer in Medisix Therapeutics, a company focused on developing novel immune cell therapies.
  • Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics Holdings Limited, said, "We warmly welcome Dr. Baffa to join CARsgen.
  • Dr. Raffaele Baffa, Chief Medical Officer of CARsgen Therapeutics Holdings Limited, said, "I am very excited to join CARsgen.

Do Plant-Based and Blend Meat Alternatives Taste Like Meat?

Retrieved on: 
Thursday, March 24, 2022
AAEA, Agriculture, University of Parma, Organization, Wageningen University & Research, Beyond Meat, American Journal, Education, Research, American Journal of Agricultural Economics, Meat, Environment, Agricultural economics, Health, Agricultural & Applied Economics Association, Industry, Interview, Applied Economic Perspectives and Policy, Choice, AEPP, Taste, COVID, Food, University, Fast food, Policy

MILWAUKEE, March 24, 2022 /PRNewswire-PRWeb/ -- With meat prices escalating during the Ukraine crisis and the possibility of a new COVID surge, more and more are turning to a plant-based meat to save a few dollars at the grocery store.

Key Points: 
  • In the new article " Do Plant-Based and Blend Meat Alternatives Taste Like Meat?
  • We find that beef burgers are preferred over the plant-based alternatives.
  • Overall, our results suggest that the success of plant-based alternatives is heavily dependent on the taste; as well as on the way these alternative burgers are made.
  • Recognizing taste as a key factor for the expansion of plant-based meat among meat-eaters, Beyond Meat, which used pea-like protein, has adjusted the composition of its burger to even more closely resemble a typical meat flavor."

Medigus: Prof. Nancy Agmon-Levin Joins Polyrizon’s Scientific Advisory Board

Retrieved on: 
Thursday, March 3, 2022
DKFZ, Granuloma, Ben-Gurion University of the Negev, Internal medicine, University of Parma, Lupus, Private Securities Litigation Reform Act, Hives, Immunotherapy, Industry, Hadassah Medical Center, Robotics, Security (finance), German Cancer Research Center, U.S. Securities and Exchange Commission, Ownership, James v Redcats (Brands) Ltd, Chemical substance, Solution, University, MDGS, Digital, Allergy, Administration, Pharmacy, Angioedema, Antiphospholipid syndrome, Immunology, Sheba Medical Center, Degenerative disease, Lists of diseases, Regenerative medicine, Hebrew University of Jerusalem, Faculty, Chemical engineering, Autoimmune disease, GLOBE, Immunodeficiency, Vaccine, Online gambling, Pharmaceutical industry

Tel Aviv, Israel, March 03, 2022 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle (“EV”) and charging solutions, announced today that Polyrizon Ltd., a privately held company in which Medigus owns 37.03%, has added Prof. Nancy Agmon-Levin, expert in immunology, allergy, internal medicine, to its scientific advisory board. 

Key Points: 
  • Prof. Agmon- Levin is the Head of the Clinical Immunology, Angioedema and Allergy Unit, Lupus and Autoimmune Diseases Clinic at Sheba Medical Center.
  • Prof. Agmon-Levin is a co-author of numerous scientific articles.
  • Prof. Agmon-Levin joins a scientific advisory board that already includes distinguished professors in the fields of biomaterials, drug delivery systems and nasal administrated products.
  • The current composition of Polyrizons scientific advisory board members include:
    Prof. Smadar Cohen - Distinguished Professor and Director of the Regenerative Medicine and Stem Cell Research Center at Ben Gurion University of the Negev.

Medigus: Polyrizon to Test its Product Candidate for Protection Against the Highly Transmissible Corona Virus Omicron Variant

Retrieved on: 
Thursday, December 23, 2021
Degenerative disease, U.S. Securities and Exchange Commission, Vaccination, Nasdaq, CDC, Virus, Omicron, Risk, Private Securities Litigation Reform Act, Coronavirus, P.1, VOC, Ownership, MDGS, Infection, Industry, COVID-19, University of Parma, Solution, Department, Gamma, Severe acute respiratory syndrome coronavirus 2, Security (finance), Robotics, GLOBE, Vaccine, Digital, Pharmaceutical industry, Delta

This study follows recent pre-clinical studies showed strong potential against human coronavirus 229E and influenza virus infection.

Key Points: 
  • This study follows recent pre-clinical studies showed strong potential against human coronavirus 229E and influenza virus infection.
  • Polyrizon is planning to assess the protection effect of its Capture and Contain (C&C) platform against the recently reported emerged variant.
  • The frequently emerging new highly contagious COVID-19 variants highlights the need for prevention solutions to reduce the infection and transmission of these viruses.
  • In an ongoing pre-clinical studies Polyrizon product is tested for Protection against the high transmissible corona viruses, the Delta variant lineage B.1.617.2 and the Gamma variant lineage P.1.

ElectReon Brings Wireless Inductive Electric Vehicle Charging Technology to Italy’s “Arena of the Future”

Retrieved on: 
Thursday, December 2, 2021
Trucking, Environment, Transport, Automotive, Other Technology, Public Policy, Other Policy Issues, Urban Planning, Hardware, Logistics, Supply Chain Management, Technology, Construction & Property, Public Policy, Government, Utilities, Alternative Energy, Energy, General Automotive, Public Transport, GHG, Invention, Carbon, Adoption, Mapei, Anxiety, CEO, Calibration, TIM, Technology, Â, Industry, ERS, EVS, CAAS, University, Solution, Electric road, City, Roma Tre University, Policy, Iveco Bus, IVECO, Arena, Efficiency, Ownership, ABB, University of Parma, Multimedia, Future, Wireless, TASE, EV, Renewable energy, Mobile phone

ElectReon (TASE: ELWS.TA), the leading provider of inductive in-road charging technology for commercial and passenger electric vehicles, announced the launch of the Arena of the Future'' project in Brescia, Italy where the company has integrated its wireless technology to charge an IVECO bus and Stellantiss Fiat Nuova 500 passenger vehicle while driving.

Key Points: 
  • ElectReon (TASE: ELWS.TA), the leading provider of inductive in-road charging technology for commercial and passenger electric vehicles, announced the launch of the Arena of the Future'' project in Brescia, Italy where the company has integrated its wireless technology to charge an IVECO bus and Stellantiss Fiat Nuova 500 passenger vehicle while driving.
  • Starting today, the Arena of the Future is showcasing ElectReons inductive EV charging technology as a technological enabler of an immediate, concrete solution to decarbonize the mobility sector.
  • ElectReons technology can be adapted to any electric vehicle, from a passenger vehicle to commercial truck, creating a shared platform for a zero emissions mobility system at scale.
  • ElectReons wireless charging technology enables vehicles to charge as they drive at any speed on electrified highways.

Clinical data published in Clinical Microbiology and Infection support use of MeMed’s test in reducing antibiotic overuse in children

Retrieved on: 
Wednesday, December 1, 2021
Autopilot, Royal commission, Pediatric Clinics of North America, Patient, Genetically modified bacteria, Defense, CEO, European Commission, Protein, Infection, Technology, PLOS One, Adolescent medicine, CRP, Urinary tract infection, University, Internet meme, Medical microbiology, Solution, Lancet, Ministry, Physician, Fever, AMR, University of Parma, FDA, Pediatrics, Degenerative disease, CE marking, Trial of the century, Clinic, Pharmaceutical industry, Vaccine

The study, funded by the EU commission, has been published in Clinical Microbiology and Infection .

Key Points: 
  • The study, funded by the EU commission, has been published in Clinical Microbiology and Infection .
  • Dr. Eran Eden, MeMeds co-founder and CEO said: Data drives everything we do at MeMed.
  • We are grateful to the European Commission for funding the study, and to our clinical collaborators who lead it.
  • These data show that host response tests have an important role to play in treatment guidance in children with acute infection.

Clinical data published in Clinical Microbiology and Infection support use of MeMed’s test in reducing antibiotic overuse in children

Retrieved on: 
Wednesday, December 1, 2021
Autopilot, Royal commission, Pediatric Clinics of North America, Patient, Genetically modified bacteria, Defense, CEO, European Commission, Protein, Infection, Technology, PLOS One, Adolescent medicine, CRP, Urinary tract infection, University, Internet meme, Medical microbiology, Solution, Lancet, Ministry, Physician, Fever, AMR, University of Parma, FDA, Pediatrics, Degenerative disease, CE marking, Trial of the century, Clinic, Pharmaceutical industry, Vaccine

The study, funded by the EU commission, has been published in Clinical Microbiology and Infection .

Key Points: 
  • The study, funded by the EU commission, has been published in Clinical Microbiology and Infection .
  • Dr. Eran Eden, MeMeds co-founder and CEO said: Data drives everything we do at MeMed.
  • We are grateful to the European Commission for funding the study, and to our clinical collaborators who lead it.
  • These data show that host response tests have an important role to play in treatment guidance in children with acute infection.

Correcting Quantum Computing Platforms Study Wins 2021 Advances in Magnetism Award

Retrieved on: 
Monday, September 20, 2021
Publishing, Magnetism, AIP, American Institute of Physics, Conference, Multimedia, Method, Journal of Magnetism and Magnetic Materials, University, American Institute, University of Parma, View, Architecture, Research, MMM, AIP Advances, Travel, Computer data storage

MELVILLE, N.Y., Sept. 20, 2021 /PRNewswire/ --A study on working toward a scalable architecture for quantum computing by using molecular spins for error correction and logical operations won the Advances in Magnetism Award, sponsored by AIP Advances, published by AIP Publishing.

Key Points: 
  • MELVILLE, N.Y., Sept. 20, 2021 /PRNewswire/ --A study on working toward a scalable architecture for quantum computing by using molecular spins for error correction and logical operations won the Advances in Magnetism Award, sponsored by AIP Advances, published by AIP Publishing.
  • Alessandro Chiesa, a research associate at the University of Parma, received a cash award and travel stipend to the next in-person Magnetism and Magnetic Materials conference.
  • "Developing and implementing techniques, such as error correction, provide a foundation for quantum computing at a larger scale."
  • To be eligible for the Advances in Magnetism Award, an MMM conference paper must be accepted for publication in AIP Advances.